Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease

NCT04974099 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped This was the Pilot study. The larger, confirmatory study has started

Conditions

Crohn Disease

Interventions

DEVICE: RoadMAB precision dashboard
DRUG: Infliximab precision dosing

Sponsor

Children's Hospital Medical Center, Cincinnati

Collaborators

[object Object]